Related Experiment Video
Updated: Jul 4, 2026

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension
Published on: May 17, 2024
Homocysteinemia in hypertensive patients with renal target organ damage (mild renal dysfunction)
N R Robles1, J F Sanchez Munoz-Torrero, F Garcia Gallego
1Servicio de Nefrologia, Hospital Infanta Cristina, Carretera de Portugal s/n 06070, Badajoz, Spain. nroblesp@senefro.org
Insights
Hypertensive patients with mild renal dysfunction exhibit elevated homocysteine levels, suggesting increased cardiovascular risk. This study highlights the importance of monitoring homocysteine in this patient group.
Area of Science:
- Nephrology
- Cardiology
- Clinical Biochemistry
Background:
- Hypertension is a common comorbidity with renal dysfunction.
- Elevated homocysteine levels are associated with increased cardiovascular risk.
- The relationship between mild renal dysfunction and homocysteine in hypertensive patients is not well-established.
Purpose of the Study:
- To investigate the prevalence of high plasmatic homocysteine levels in hypertensive patients with mild renal dysfunction (MRD).
- To compare homocysteine levels in MRD patients with hypertensive controls and chronic renal failure (CRF) patients.
Main Methods:
- Cross-sectional study comparing three groups: MRD patients, hypertensive controls, and CRF patients.
- Blood samples analyzed for plasmatic creatinine and homocysteine levels.
- Creatinine clearance calculated for each group.
Main Results:
- MRD patients (n=18) showed significantly higher homocysteine levels (14.8 ± 5.5 µmol/l) compared to controls (11.0 ± 4.3 µmol/l; p=0.007).
- CRF patients (n=29) had the highest homocysteine levels (19.3 ± 7.1 µmol/l).
- MRD patients had significantly lower creatinine clearance (54.5 ± 9.4 ml/min) than controls (88.9 ± 18.9 ml/min).
Conclusions:
- Hypertensive patients with mild renal dysfunction present with elevated homocysteine levels.
- This finding may contribute to the increased cardiovascular risk observed in this population.
- Monitoring homocysteine levels in hypertensive patients with MRD is recommended.
Abstract:
The prevalence of high plasmatic levels of homocysteine in hypertensive patients with mild renal dysfunction (MRD) defined by 2003 European Hypertension Society Guidelines (men plasmatic creatinine between 1.3 and 1.5; women plasmatic creatinine between 1.2 and 1.4 mg/dl) has not been previously reported. To evaluate this item 18 MRD patients were recruited (54% males, mean age 59.2 +/- 17.3 years, mean plasmatic creatinine 1.30 +/- 0.12 mg/dl). They were compared with a control group of hypertensives with normal renal function (n = 87, 42,9% males, mean age 53.6 +/- 12.3 years, mean plasmatic creatinine 0.83 +/- 0.21 mg/dl) and a group of 29 chronic renal failure patients (51.7% males, mean age 56.9 +/- 15.0 years, mean plasmatic creatinine 2.39 +/- 0.95 mg/dl). Age and sex differences are not significant, plasmatic creatinine levels are different among three groups (p <0.001, t student test). Basal homocysteine levels of CRF (19.3 +/- 7.1 micromol/l) were higher than those of control group (11,0 +/- 4,3 micromol/l) and MRD patients (14.8 +/- 5.5 micromol/l; p = 0.027 vs. CRF and p = 0.007 vs. control, Mann-Whitney test). Mean creatinine clearance was 30.3 +/- 11.5 ml/min for CRF group, significantly lower than MRD patients creatinine clearance (54.5 +/- 9.4 ml/min, p <0.001, t student test) and control ones (88,9 +/- 18,9 ml/min, p <0.001, t student test). Hypertensive patients with mild renal dysfunction showed higher and pathological levels of homocysteinemia as compared with controls, this finding might be related to the higher cardiovascular risk described in this group of patients.
Related Concept Videos
Hypertension III: Clinical Manifestations and Diagnostic Studies
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Hypertension II: Pathophysiology
